Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(1):47-51
DOI: 10.5428/pcar20190112
Risk of cardiac failure induced by saxagliptin in patients with type 2 diabetes mellitus:a meta analysis
1. HUANG Wenhui(Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affilated to Xiamen Univesty,Fujian Zhangzhou 363000,China hwhui175@163.com)
2. ZHANG Minghui(Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affilated to Xiamen Univesty,Fujian Zhangzhou 363000,China )
3. XIE Fenghua(Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affilated to Xiamen Univesty,Fujian Zhangzhou 363000,China )
4. XUE Honglin(Department of Pharmacy,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affilated to Xiamen Univesty,Fujian Zhangzhou 363000,China asctx472@126.com)
ABSTRACT  Objective: To systematically evaluate the relationship between saxagliptin and risk of cardiac failure in type 2 diabetes patients.Methods: All the related literature was retrieved from the databases such as China Science and Technology Journal Database(VIP),Wanfang Data Digitalization Journals,China National Knowledge Infrastructure(CNKI),PubMed and Cochrane library from the inception to December 2017.The randomized controlled trails(RCTs) about cardiac failure induced by saxagliptin in type 2 diabetes patients were collected,the data was screened and the quality of the included RCTs was assessed.Then,meta analysis was performed using RevMan 5.3 software.Results: A total of 11 RCTs were included.Meta-analysis showed that saxagliptin caused higher risk of cardiac failure than that in the control group(RR=1.20,95%CI 1.02 to 1.42,P=0.03).Further research revealed that 5 mg/d saxagliptin monotherapy or combined therapy also induced higher risk of cardiac failure than that in the control group[RR=1.24,95%CI(1.05,1.46),P=0.01].However,2.5 or 10 mg/d saxagliptin,regardless of monotherapy or combined therapy,had similar risk of cardiac failure as the control group[2.5 mg/d saxagliptin RR=0.69,95%CI(0.31,1.55),P=0.37;10 mg/d saxagliptin RR=0.18,95%CI(0.02,1.67),P=0.13].Conclusion: Saxagliptin at a dose of 5 mg/d may increase risk of cardiac failure,while other doses of saxagliptin are not correlated with the increased risk of cardiac failure.However,its long-term safety still remans to be confirmed by more high-quality,large-sample RCTs with long-term follow-ups.
Welcome to PCAR! You are the number 191 reader of this article!
Please cite this article as:
HUANG Wenhui,ZHANG Minghui,XIE Fenghua,XUE Honglin,. Risk of cardiac failure induced by saxagliptin in patients with type 2 diabetes mellitus:a meta analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 47-51.
References:
1. Toth P P.Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease[J].Vasc Health Risk Manag,2015,23(11):9-23.
2. Konya H,Yano Y,Matsutani S,et al.Profile of saxagliptin in the treatment of type 2 diabetes:focus on Japanese patients[J].Ther Clin Risk Manag,2014,11(10):547-558.
3. Scirica B M,Bhatt D L,Braunwald E,et al.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J].N Engl J Med,2013,369(14):1317-1326.
4. US Food and Drug Administration.FDA Drug Safety Communication:FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin[EB/OL].(2014-02)[2018-01-02].https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm.
5. The Cochrane Collaboration.Cochrane handbook for systematic reviews of interventions (version 5.1.0)[EB/OL].(2011-03)[2018-01-02].http://handbook.cochrane.org/.
6. AstraZeneca.Saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise[EB/OL].(2015-04)[2018-01-02].https://clinicaltrials.gov/ct2/show/results/NCT00121641?sect=X43z0156_08#othr.
7. AstraZeneca.Study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with metformin alone[EB/OL].(2015-04)[2018-01-02].https://clinicaltrials.gov/ct2/show/study/NCT00121667?sect=X30156.
8. AstraZeneca.A study assessing saxagliptin treatment in type 2 diabetic subjects who are not controlled with TZD therapy alone[EB/OL].(2015-04)[2018-01-02].https://clinicaltrials.gov/ct2/show/results/NCT00295633?sect=X30156#evnt.
9. AstraZeneca.Study of BMS-477118 as monotherapy with titration in subjects with type 2 diabetes who are not controlled with diet and exercise[EB/OL].(2015-04)[2018-01-02].https://clinicaltrials.gov/ct2/show/NCT00316082?term=00316082&rank=1.
10. AstraZeneca,Bristol-Myers.A phase 3 study of BMS-477118 in combination with metformin in subjects with type 2 diabetes who are not controlled with diet and exercise[EB/OL].(2015-04)[2018-01-02].https://clinicaltrials.gov/ct2/show/NCT00327015?cond=00327015&rank=1.
11. AstraZeneca,Bristol-Myers Squibb.52-week add-on to metformin comparison of saxagliptin and sulphonylurea,with a 52-week extension period[EB/OL].(2012-03)[2018-01-02].https://clinicaltrials.gov/ct2/show/results/NCT00575588?sect=X30156#evnt.
12. AstraZeneca,Bristol-Myers Squibb.Treatment effect of saxagliptin compared with placebo in patients with type 2 diabetes and renal impairment[EB/OL].(2011-05)[2018-01-02].https://clinicaltrials.gov/ct2/show/NCT00614939?term=00 614939&rank=1.
13. AstraZeneca.Safety and efficacy of saxagliptin plus insulin with or without metformin[EB/OL].(2015-06)[2018-01-02].https://clinicaltrials.gov/ct2/show/results/NCT00757 588?sect=X30156#evnt.
14. AstraZeneca,Bristol-Myers Squibb.Saxagliptin compared to glimepiride in elderly type 2 diabetes patients,with inadequate glycemic control on metformin(generation)[EB/OL].(2013-11)[2018-01-02].https://clinicaltrials.gov/ct2/show/study/NCT01006603?sect=X30156.
15. AstraZeneca,Bristol-Myers Squibb.Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications(SAVOR-TIMI 53)[EB/OL].(2014-07)[2018-01-02].https://clinicaltrials.gov/ct2/show/study/NCT01107886?sect=X30156.
16. Matthaei S,Catrinoiu D,Celiński A,et al.Randomized,double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes[J].Diabetes Care,2015,38(11):2018-2024.
17. McMurray J J V,Ponikowski P,Bolli G B,et al.Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure:a randomized placebo-controlled trial[J].J Am Coll Cardiol HF,2018,6(1):8-17.
18. Ayaori M,Iwakami N,Uto-Kondo H,et al.Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients[J].J Am Heart Assoc,2013,2(1):e003277.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口